Skip to main content
Top
Published in: Clinical Rheumatology 11/2008

01-11-2008 | Original Article

Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus

Authors: Ahmed M. Abdel-Nasser, Rasha M. Ghaleb, Jehan A. Mahmoud, Wafaa Khairy, Refaat M. Mahmoud

Published in: Clinical Rheumatology | Issue 11/2008

Login to get access

Abstract

The objective of our study was to determine the prevalence of neuropsychiatric manifestations and anti-ribosomal P antibodies (aRP) in SLE and to examine the diagnostic utility and associations of aRP with neuropsychiatric and other disease manifestations. Thirty two consecutive SLE patients, diagnosed according to the updated 1997 ACR criteria, were studied. A full medical history, rheumatological, neurological, psychiatric examination, and psychometric evaluation, including a battery of tests for cognitive dysfunction and the Symptom Checklist-90-Revised depression and anxiety scales were administered to all patients. Disease activity was scored using the SLEDAI. Neuropsychiatric manifestations were diagnosed and categorized according to the 1999 ACR case definitions for 19 NPSLE syndromes. Laboratory and serologic tests including ANA, anti-ds DNA, anti-cardiolipin antibodies (aCL) and aRP (ELISA) were also carried out. Twenty six (81.2%) patients had one or more NP manifestations. Depression (59.4%), headache (46.9%) and cognitive dysfunction (37.5%) were the commonest NPSLE syndromes. Other less commonly detected manifestations included seizures, anxiety, acute confusional state, stroke, and psychosis. aRP was positive in seven (21.9%) patients, all of whom had one or more NPSLE syndromes. Patients with psychiatric manifestations in general and mood disorders in particular had significantly higher mean titers of aRP than patients without these disorders (p < 0.05). aRP were found to be significantly associated with a younger age at the onset of SLE, with more severe articular manifestations and with the presence but not the severity of depression. aRP were highly specific for NPSLE and depression, and they were highly sensitive for psychosis. Neuropsychiatric manifestations are found in 81.2% of unselected Egyptian SLE patients. The presence of aRP antibodies positively predicts patients with psychiatric manifestations in general and mood disorders in particular, for which aRP is specific, but not sensitive. However, aRP is sensitive for psychosis, so that its absence in patients with SLE may help exclude Lupus psychosis.
Literature
1.
go back to reference Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308CrossRef Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308CrossRef
2.
3.
go back to reference Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308–318PubMedCrossRef Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308–318PubMedCrossRef
4.
go back to reference Jacobsen S, Petersen J, Ullman S et al (1998) A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol 17:478–484PubMedCrossRef Jacobsen S, Petersen J, Ullman S et al (1998) A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol 17:478–484PubMedCrossRef
5.
go back to reference Hanly JG, McCurdy G, Fougere L et al (2004) Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 31:2156–2162PubMed Hanly JG, McCurdy G, Fougere L et al (2004) Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 31:2156–2162PubMed
6.
go back to reference Ainiala H, Loukkola J, Peltola J et al (2001) The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496–500PubMed Ainiala H, Loukkola J, Peltola J et al (2001) The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496–500PubMed
7.
go back to reference Brey RL, Holliday SL, Saklad AR et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214–1220PubMed Brey RL, Holliday SL, Saklad AR et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214–1220PubMed
8.
go back to reference ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRef ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRef
9.
go back to reference Hanly JG, Hong C, Smith S et al (1999) A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 42:728–734PubMedCrossRef Hanly JG, Hong C, Smith S et al (1999) A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 42:728–734PubMedCrossRef
10.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
11.
go back to reference Elkon KB, Parnassa AP, Foster CL (1985) Lupus autoantibodies target ribosomal P proteins. J Exp Med 162:459–471PubMedCrossRef Elkon KB, Parnassa AP, Foster CL (1985) Lupus autoantibodies target ribosomal P proteins. J Exp Med 162:459–471PubMedCrossRef
12.
go back to reference Schneebaum AB, Singleton JD, West SG et al (1991) Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythamatosus. Am J Med 90:54–62PubMedCrossRef Schneebaum AB, Singleton JD, West SG et al (1991) Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythamatosus. Am J Med 90:54–62PubMedCrossRef
13.
go back to reference Nojima Y, Minota S, Yamada A et al (1992) Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 51:1053–1055PubMedCrossRef Nojima Y, Minota S, Yamada A et al (1992) Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 51:1053–1055PubMedCrossRef
14.
go back to reference Press J, Palayew K, Laxer RM et al (1996) Anti-ribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 99:671–676CrossRef Press J, Palayew K, Laxer RM et al (1996) Anti-ribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 99:671–676CrossRef
15.
go back to reference Sato T, Uchiumi T, Ozawa T et al (1991) Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 18:1681–1684PubMed Sato T, Uchiumi T, Ozawa T et al (1991) Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 18:1681–1684PubMed
16.
go back to reference van Dam A, Nossent H, de Jong J et al (1991) Diagnostic value of antibodies against ribosomal phosphoproteins: a cross sectional and longitudinal study. J Rheumatol 18:1026–1034PubMed van Dam A, Nossent H, de Jong J et al (1991) Diagnostic value of antibodies against ribosomal phosphoproteins: a cross sectional and longitudinal study. J Rheumatol 18:1026–1034PubMed
17.
go back to reference American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington (DC) American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington (DC)
18.
go back to reference El-Behairy AA (1984) The Symptom Checklist-90-R. Cairo, El-Nahda El-Misrya El-Behairy AA (1984) The Symptom Checklist-90-R. Cairo, El-Nahda El-Misrya
19.
go back to reference Wechsler D (1981) Wechsler adult intelligence scale-revised manual. Psychological, New York Wechsler D (1981) Wechsler adult intelligence scale-revised manual. Psychological, New York
20.
go back to reference Wechsler D (1971) Wechsler memory scale. Psychological, New York Wechsler D (1971) Wechsler memory scale. Psychological, New York
21.
go back to reference Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI.A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI.A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef
22.
go back to reference Uribe AG, Vilá LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcón GS (2004) The systemic Lupus activity measure-revised, the Mexican systemic Lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 31:1934–1940PubMed Uribe AG, Vilá LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcón GS (2004) The systemic Lupus activity measure-revised, the Mexican systemic Lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 31:1934–1940PubMed
23.
go back to reference Tzioufas AG, Tzortzakis NG, Panou-Pomonis E et al (2000) The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 59:99–104PubMedCrossRef Tzioufas AG, Tzortzakis NG, Panou-Pomonis E et al (2000) The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 59:99–104PubMedCrossRef
24.
go back to reference Karassa FB, Loannidis JP, Toulomi G et al (2000) Risk factor for CNS involvement in systemic lupus erythematosus. QJM 93:169–174PubMedCrossRef Karassa FB, Loannidis JP, Toulomi G et al (2000) Risk factor for CNS involvement in systemic lupus erythematosus. QJM 93:169–174PubMedCrossRef
25.
go back to reference Mok CC, Lau CS, Wong RWS et al (2001) Neuropsychatric manifestations and their clinical association in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 28:766–771PubMed Mok CC, Lau CS, Wong RWS et al (2001) Neuropsychatric manifestations and their clinical association in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 28:766–771PubMed
26.
go back to reference Isshi K, Hirohata S (1996) Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 39:1483–1490PubMedCrossRef Isshi K, Hirohata S (1996) Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 39:1483–1490PubMedCrossRef
27.
go back to reference Teh L-S, Lee MK, Wang F et al (1993) Anti-ribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus. Br J Rheum 32:663–665CrossRef Teh L-S, Lee MK, Wang F et al (1993) Anti-ribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus. Br J Rheum 32:663–665CrossRef
28.
go back to reference Abdel-Nasser AM, Abd El-Azim S, Taal E et al (1998) Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 37:391–397PubMedCrossRef Abdel-Nasser AM, Abd El-Azim S, Taal E et al (1998) Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 37:391–397PubMedCrossRef
29.
go back to reference Arnett FC, Reveille JD, Moustopoulos HM et al (1996) Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum 39:1833–1839PubMedCrossRef Arnett FC, Reveille JD, Moustopoulos HM et al (1996) Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum 39:1833–1839PubMedCrossRef
30.
go back to reference Sfikakis PP, Mitsikostas DD, Manoussakis MN et al (1998) Headache in systemic lupus erythematosus. Br J Rheumatol 37:300–303PubMedCrossRef Sfikakis PP, Mitsikostas DD, Manoussakis MN et al (1998) Headache in systemic lupus erythematosus. Br J Rheumatol 37:300–303PubMedCrossRef
31.
go back to reference Appenzeller S, Costallat LT (2004) Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia 24:1013–1015CrossRef Appenzeller S, Costallat LT (2004) Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia 24:1013–1015CrossRef
32.
go back to reference Weiner S, Otte A, Schumacher M et al (2000) Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 59:377–385PubMedCrossRef Weiner S, Otte A, Schumacher M et al (2000) Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 59:377–385PubMedCrossRef
33.
go back to reference Harrison MJ (2002) Cognitive dysfunction in neuropsychiatric systemic lupus erythematosus. Curr Opin Rheumatol 14:510–514PubMedCrossRef Harrison MJ (2002) Cognitive dysfunction in neuropsychiatric systemic lupus erythematosus. Curr Opin Rheumatol 14:510–514PubMedCrossRef
34.
go back to reference Sanna G, Bertolaccini ML, Cuadrado MJ et al (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed Sanna G, Bertolaccini ML, Cuadrado MJ et al (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed
35.
go back to reference Teh L-S, Isenberg DA (1994) Anti-ribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum 37:307–315PubMedCrossRef Teh L-S, Isenberg DA (1994) Anti-ribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum 37:307–315PubMedCrossRef
36.
go back to reference Teh L-S, Bedwell AE, Isenberg DA et al (1992) Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 51:489–494PubMedCrossRef Teh L-S, Bedwell AE, Isenberg DA et al (1992) Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 51:489–494PubMedCrossRef
37.
go back to reference Reichlin M, Broyles TF, Hubscher O et al (1999) Prevalence of autoantibodies to ribosomal P proteins in juvenile onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 42:69–75PubMedCrossRef Reichlin M, Broyles TF, Hubscher O et al (1999) Prevalence of autoantibodies to ribosomal P proteins in juvenile onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 42:69–75PubMedCrossRef
38.
go back to reference Ghirardello A, Doria A, Zampieri S et al (2000) Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum 59:975–981CrossRef Ghirardello A, Doria A, Zampieri S et al (2000) Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum 59:975–981CrossRef
39.
go back to reference Karassa FB, Afeltra A, Ambrozic A et al (2006) Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 54:312–324PubMedCrossRef Karassa FB, Afeltra A, Ambrozic A et al (2006) Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 54:312–324PubMedCrossRef
Metadata
Title
Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus
Authors
Ahmed M. Abdel-Nasser
Rasha M. Ghaleb
Jehan A. Mahmoud
Wafaa Khairy
Refaat M. Mahmoud
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 11/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0921-1

Other articles of this Issue 11/2008

Clinical Rheumatology 11/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.